Fig. 1: SARS-CoV-2 entry/infection and replication assays on imatinib and asciminib. | Leukemia

Fig. 1: SARS-CoV-2 entry/infection and replication assays on imatinib and asciminib.

From: Imatinib is not a potent anti-SARS-CoV-2 drug

Fig. 1

a Single-round virus entry/infection assay was performed in Caco-2 cells using pseudotyped SARS-Cov-2 virus with S proteins as the envelope. Cells were pre-treated with drugs for 1 h before adding the virus. Infected cells (GFP+) were quantified by flow cytometry after 48 h. b–d Virus replication assay were performed in Caco-2 cells with USA-WA1/2020 strain of SARS-CoV-2. Drugs were added to 5 wells of a 96-well plate with 60–80% confluency. Three wells of each dilution were infected with virus, and two wells remained uninfected as toxicity controls. SARS-CoV-2 was added to achieve a multiplicity of infection (MOI) of ~0.002, and supernatant viral titer was quantified after 3 days by a standard endpoint dilution CCID50 assay. Remdesivir was tested in parallel as a positive control.

Back to article page